Copyright
©The Author(s) 2022.
World J Methodol. Sep 20, 2022; 12(5): 402-413
Published online Sep 20, 2022. doi: 10.5662/wjm.v12.i5.402
Published online Sep 20, 2022. doi: 10.5662/wjm.v12.i5.402
Table 2 Guideline recommendations for treatment of subclinical hypothyroidism
Degree of subclinical hypothyroidism | ATA 2012[36] | ETA 2013[37] | NICE 2019[38] |
TSH > 10 mIU/L | Levothyroxine should be considered. (Grade B) | Younger patients (< 65 to 70 yr): Treatment with levothyroxine is recommended, even in the absence of symptoms. (Grade 2); Older patients (> 70 yr): Treatment with levothyroxine should be considered if clear symptoms of hypothyroidism are present or if the risk of vascular events is high. (Not a graded recommendation, but part of the treatment algorithm) | All adults (on 2 occasions, 3 mo apart) consider treatment. |
TSH: ULN to 10 mIU/L | Treatment should be considered on the basis of individual factors (i.e., symptoms suggestive of hypothyroidism, a positive test for antibodies to thyroid peroxidase, or evidence of atherosclerotic cardiovascular disease, heart failure, or associated risk factors for these diseases). (Grade B, because of a lack of randomized, controlled trials) | Younger patients (< 65 to 70 yr): A trial period of treatment with levothyroxine should be considered when symptoms suggestive of hypothyroidism are present. (Grade 2); Older patients (especially > 80 to 85 yr): Careful follow-up with a wait-and-see strategy, generally avoiding hormonal treatment, is recommended. (Grade 3) | Age < 65 years (on 2 occasions, 3 mo apart): Consider a 6-mo trial of levothyroxine if symptoms are present. |
- Citation: Mittal M, Jethwani P, Naik D, Garg MK. Non-medicalization of medical science: Rationalization for future. World J Methodol 2022; 12(5): 402-413
- URL: https://www.wjgnet.com/2222-0682/full/v12/i5/402.htm
- DOI: https://dx.doi.org/10.5662/wjm.v12.i5.402